Buprenorphine Extended-Release Injection (Tradename: Sublocade) is a long acting monthly subcutaneous injectable opioid for use in patients with moderate to severe opioid use disorder. It is the long-acting form of sublingual Suboxone.
7
consecutive days prior to initiating Sublocade therapy.If discontinued, patients should be monitored for several months for signs and symptoms of opioids withdrawal and treated appropriately. After steady-state has been achieved (4-6 months), patients discontinuing Sublocade may have detectable plasma levels of buprenorphine for 12 months or longer. The correlation between plasma concentrations of buprenorphine and those detectable in urine is not known.